Belfort et al. randomly assigned 55 patients with biopsy-confirmed NASH and either impaired glucose tolerance or type 2 diabetes to receive a hypocaloric diet plus either pioglitazone (30 mg daily ...

This game-changing medication, used in conjunction with diet and exercise, targets noncirrhotic NASH—a serious liver condition—associated with moderate to advanced liver fibrosis. For over 15 ...

Investigators have found that the gene Asah1 plays a crucial protective role in preventing the progression of nonalcoholic fatty liver diseases (NAFLD) into more severe forms of liver disease by ...